STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds
STAT
OCTOBER 25, 2023
The other scenario involved treatments that were more expensive, but no more effective than alternatives, such as the Abraxane chemotherapy. The researchers examined Medicare beneficiaries who were diagnosed with cancer and received treatment from 2014 through 2019.
Let's personalize your content